systemic%20lupus%20erythematosus
SYSTEMIC LUPUS ERYTHEMATOSUS
Systemic lupus erythematosus is a chronic, multisystem, inflammatory, autoimmune disorder characterized by formation of autoantibodies directed against self-antigens and immune-complex formation.
It can be suspected when ≥2 organ systems are involved.
It is predominantly diagnosed in females of childbearing age, rarely diagnosed before 8 years old.
Clinical presentation varies in different patients and the disease activity varies over time in a single patient. Majority of patients have arthralgia of the hand.

Introduction

  • Predominantly diagnosed in females of childbearing age
    • Rarely diagnosed before 8 years old
  • Clinical presentation varies in different patients & the disease activity varies over time in a single patient
    • Majority of patients have arthralgia of the hand

Definition

  • Systemic lupus erythematosus (SLE) is a chronic, multisystem, inflammatory, autoimmune disorder characterized by formation of autoantibodies directed against self-antigens & immune-complex formation
    • SLE can be suspected when ≥2 organ systems are involved

Signs and Symptoms

Clinical features of systemic lupus erythematosus (SLE)

  • Cardiac
    • Endocarditis
    • Myocarditis
    • Pericarditis
  • Constitutional
    • Fatigue
    • Fever
    • Weight loss
  • Dermatological
    • Alopecia
    • Butterfly rash
    • Mucous membrane lesion
    • Photosensitivity
    • Purpura
    • Raynaud’s phenomenon
    • Urticaria
    • Vasculitis
  • Gastrointestinal
    • Abdominal pain
    • Nausea, vomiting
  • Hematologic
    • Anemia
    • Leukopenia
    • Thrombocytopenia
  • Musculoskeletal
    • Arthralgia
    • Arthritis
    • Myositis
  • Neuropsychiatric
    • Cranial neuropathies
    • Organic brain syndrome
    • Peripheral neuropathies
    • Psychosis
    • Seizures
    • Transverse myelitis
  • Pulmonary
    • Pleurisy
    • Pulmonary hypertension
    • Pulmonary parenchyma
  • Renal
    • Casts
    • Hematuria
    • Nephrotic syndrome
    • Proteinuria
  • Reticuloendothelial
    • Hepatomegaly
    • Lymphadenopathy
    • Splenomegaly
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Elvira Manzano, 17 Oct 2017
Bisphosphonates have proven antifracture efficacy and remain to be the cornerstone of osteoporosis treatment. However, a drug holiday is of particular importance with bisphosphonates due to some signals with long-term use of the drug, including rare incidence of atypical femoral fracture (AFF) and osteonecrosis of the jaw (ONJ), says a leading endocrinologist at AFOS 2017.
Kavitha G. Shekar, 14 Jun 2016
The incidence of type 1 diabetes mellitus (T1D) was found to be higher in juvenile idiopathic arthritis patients (JIA) compared with the general population, said German researchers at the European League Against Rheumatism Annual Congress (EULAR 2016) held in London, UK.
Elaine Tan, 29 Jun 2017

Tofacitinib, a first-in-class Janus kinase (JAK) inhibitor, shows promise as an oral treatment with quick onset of action and sustained efficacy in patients with psoriatic arthritis (PsA) who do not respond adequately to conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs). 

Dr. Priscilla Wong, Dr. Lydia Tam, Prof. LS Tam, 10 Nov 2017
This case report highlights that psoriatic arthritis is a heterogenous disease affecting multiple disease domains, and effective treatment requires thorough assessment of each of these different domains.